Siddharth Krishnan, PhD | Founder and Principal Consultant, Cellvanta Ltd

Portrait of Dr. Siddharth Krishnan, Founder and Principal Consultant at Cellvanta Ltd, specializing in analytical development, CMC strategy, and advanced cell and gene therapies.

Siddharth Krishnan, PhD | Founder and Principal Consultant, Cellvanta Ltd

Biography

Siddharth (Sid) Krishnan is the founder of Cellvanta, an independent scientific and technical consultancy supporting advanced-therapy development. With over 10 years of experience across academia and industry, his expertise spans analytical development and CMC strategy for ATMP development with a focus on flow cytometry, cell-based assays, potency strategy and product characterisation.

He previously worked at the Cell and Gene Therapy Catapult, supporting analytical development across different cell therapy platforms and external programmes, before joining Quell Therapeutics, where he led analytical research supporting CAR-Treg programmes. An immunologist and flow-cytometry scientist by training, his work has focused on characterising complex cell therapy products and generating the portfolio of evidence needed to guide their development.

Through Cellvanta, Sid works across the ATMP ecosystem to help organisations navigate technical uncertainty and connect analytical evidence with development decisions for programmes. He is particularly interested in increasing the accessibility of ATMPs to patients and works at the intersection of scientific rigour and practical execution to address the cost and viability of therapies emerging from promising technologies.

Interview

NanoSphere: Tell us a bit about yourself—your background, journey, and what led you to where you are today.

Siddharth: I trained as a pharmacologist during my undergraduate degree where I took a year out in industry at the Mayo Clinic before going on to do a PhD at the University of Manchester and stayed on do my postdoctoral research first in oral immune networks and subsequently, immune mechanisms linked to post-stroke cognitive decline. Despite working across varied disease contexts and models, the underlying theme was characterising targets amongst immune networks to improve outcomes in disease. And the tool central to my work was high parameter flow cytometry and dimensional reduction approaches to rapidly characterise innate and adaptive immune populations in biological contexts that were not well understood.

During the pandemic, the lab pivoted to supporting COVID-19 research where I had the opportunity characterise the immune networks that could be therapeutically targeted to improve patient outcomes. I hadn't originally planned to work in cell therapy but the project made me seek out opportunities to move closer to the development of therapies rather than remain exclusively in academic research. An opportunity at the Cell and Gene Therapy Catapult in London gave me that entry point. It was an exciting environment where I worked across different advanced-therapy platforms and with a range of collaborators. I quickly began to see how analytical development connects with process development, manufacturing, quality and the wider requirements of getting a therapy towards the clinic. I subsequently joined Quell Therapeutics, where I led analytical research supporting CAR-Treg programmes. That brought me closer to the product itself: characterisation studies, functional assessments, potency strategies and experimental evidence to support important programme decisions.

Across those roles, I became interested in the space between generating scientific data and implication of the data for a development programme: which essentially concerns technical uncertainty. For example, product characterisation, process changes, how technically sound results that do not resolve the question at hand or distinguishing assay limitations from genuine product changes and the consequences these have later in development. I founded Cellvanta to work more directly at that intersection of scientific understanding, development execution and decision-making. The aim is to help organisations identify important technical uncertainties, understand which evidence matters and support the pathway to gather evidence navigating practical and technical limitations. What continues to interest me is that combination of scientific depth and practical judgement. I enjoy understanding the technical detail, but I am equally interested in how it influences the decisions that determine whether a promising therapy can progress.

NanoSphere: You moved from hands-on analytical research at Quell Therapeutics, supporting CAR-T programmes, into a consulting role focused on CMC strategy, technical diligence, and development readiness. What did that transition teach you about how scientific decisions change when you have to consider the entire development and investment landscape?

Siddharth: A scientific decision rarely exists in isolation and is often a trade-off between priorities, money and resources which I now appreciate more fully in my consulting role. I think the biggest lesson for me has been in how I apply that principle in a risk-based way when tackling CAR-T analytics in specific development stages as it is crucial to get things right due to the far-reaching consequences.

When working on a programme, it's natural to focus on the immediate scientific questions around assays functioning as expected, the datasets generated, product understanding, etc. But looking across the wider development landscape in the context of the asset changes the question slightly. One also needs an appreciation of the questions to prioritise for the decision(s) ahead, what sufficient evidence looks like, the timelines for generating datasets and the risks around work in progress to address unresolved questions. For example, an assay can produce technically sound data without being sufficiently sensitive to distinguish a change in the product from analytical variability due to process change in a comparability exercise. Whilst acceptable during exploratory research, the analytical bar is much higher when assessing the impact of a manufacturing change, supporting a technology transfer or another development milestone due to far reaching consequences. The issue stems from analytical limitations where assays may not be suitably qualified, sensitive or robust which is critical during manufacturing.

My cross-programme experience at the Cell and Gene Therapy Catapult and product-focussed experience at Quell Therapeutics helped me appreciate how analytical development interacts with process development, manufacturing, regulatory expectations and programme timelines. I've come to see that technical risks rarely remain confined to the function in which they originate. This has influenced how I think about technical diligence and CMC strategy. I don't see technical diligence simply as identifying weaknesses. Its value is lies in technical risk management to identify competition and gaps in understanding that could impact investment decisions.

In a challenging biotech market, it has also influenced the assessment of competing technology platforms like in vivo CAR-T therapies. From a CMC perspective, it means recognising when further experimentation will genuinely improve a decision and when additional data would add cost without impact, particularly when a programme is mature and entering manufacturing.

Cellvanta combines hands-on analytical experience with a broader view of development readiness and technical risk. The aim is to help organisations understand whether their evidence, product knowledge and development plans are sufficiently aligned to support the decisions ahead. My transition reinforced that good development strategy revolves around understanding the priority of key uncertainties, gaps in understanding and the level of evidence required for decisions that gate progress to the next stage.

NanoSphere: Your current work involves helping companies determine whether technical uncertainty is a true development risk or something that can be managed through better analytical strategy. When you assess a cell or gene therapy programme, what are the first technical questions you want answered?

Siddharth: I would start with three simple but connected questions: what are we trying to develop, what do we currently understand about the product and what decision does the available evidence need to support. These questions play a key role in crystallising areas that are not priority, the gaps in understanding and evidence as well as the direction of the development pathway. It is expected that there are gaps in analytical and product understanding when development begins but it is critical to document the risks and assumptions they represent as they often shape the evolution of the CMC strategy.

The second question aims drills down on datasets around product understanding and the analytical toolbox available. Multi-omic, data rich approaches with wet-lab corroborated results is a well-trodden path but assay development and qualification can sometimes lag. Understanding assay limitations and having a strategy for assay development and qualification is critical to support comparability exercises and potency assays and clinical development. This development pipeline often provides breathing room to understand the validity of parameters measured, assay robustness and sensitivity in the setting of analytical variability. This is particularly important for cell therapies, where biological complexity, donor or starting-material variability, evolving processes and limitations in available material can make assay development challenging. With flow cytometry-based analytics being the mainstay of cell therapies, automated, optimised, qualified and low variability in assays are essential components of the analytical toolbox.

Potency is another good example where the challenge is to establish a coherent strategy in which each assay has a defined purpose and the evidence collectively supports an appropriate understanding of the product from a regulatory perspective. However, it is often extremely complex where understanding biological activity will likely require multiple orthogonal measurements from a matrix of assays that might need to be developed when the mechanism of action is complex or still evolving.

The third question is whether the analytical strategy is keeping pace with the programme. Approaching decisions such as planned process changes, scale-up activities, technology-transfers to a CDMO or clinical milestones will require unambiguous datasets generated using fit-for-purpose qualified assays. Questions around retention of suitable samples and reference materials and the comparability readiness of analytical methods being deployed will need to be addressed. This is where the concept of comparability debt becomes useful. I use the term to describe the technical uncertainty that can accumulate when product understanding, analytical capability and reference materials develop at different rates. It is not a regulatory term, but it captures a practical problem: decisions that seem reasonable early on can leave gaps that are much harder to resolve when a programme changes process or advances to another stage.

I would then ask which risk genuinely threaten the next decision and the uncertainties they are associated. Not every analytical limitation requires immediate remediation and not every uncertainty is a reason to stop a programme and risk management is key. Some risks can be managed through additional characterisation or a staged evidence generation plan. For example, these approaches are particularly salient when contracting CDMOs for manufacturing as analytical uncertainties can be external and relationship management is essential to assess their technology transfer experience and manufacturing readiness. Here, the ability to be discerning is tied to experience in the biological context, a deep understanding of the limitations of the evidence and the consequences of being wrong.

Ultimately, I would want to understand not simply whether a programme has enough data, but whether it has the right evidence to support the decision in front of it.

NanoSphere: If there's one key message or insight you'd like to share with readers about the future of nanomedicine, what would it be?

Siddharth: I think the next phase of nanomedicine is occurring as we speak where we leverage artificial intelligence, multi-omic wet lab data and patient history to understand biological complexity in health and disease and translate that understanding into safe, efficacious, accessible and cost-effective medicines.

We have made tremendous progress in developing sophisticated viral and non-viral gene delivery systems, but engineering payloads is only part of the challenge. Their targeting, behaviour in situ, inter-patient variability and manufacturability all influence whether that promise translates into clinical benefit. We need to understand not only what a system does, but why it behaves as it does and how reliably we can measure that behaviour.

We are also at the threshold of an incredibly exciting period in which the value of biotechnology increasingly extends beyond individual therapeutic products to the platforms and datasets that help us understand biology. Automated, reproducible approaches to generating high-dimensional biological data when combined with AI and machine learning, offer enormous potential. The opportunity is not simply to accumulate larger datasets, but to integrate their depth and diversity to uncover relationships, patterns and biological connections that may not be apparent through conventional experimental analysis alone. This approach is transforming how we understand disease, identify patient subgroups, predict therapeutic responses as well as adverse events and guide the development of new medicines.

Ultimately, scientific innovation is constrained to operate within the realities of clinical need, manufacturing capability and the economics of healthcare. As funding becomes more selective and competing technologies continue to evolve, the ability to demonstrate meaningful clinical advantage, develop reproducibly and justify the investment required for translation and reimbursement by healthcare system will become increasingly important. For me, the greatest opportunity lies in bringing together better engineered technologies, deeper biological understanding and increasingly powerful ways of generating and interpreting evidence. The future will not necessarily belong to the most sophisticated therapy, but to the technologies that turn scientific complexity into reliable knowledge and meaningful patient outcomes.



About

Sign up for our newsletter to stay informed with the latest insights and updates!
Search